Research programme: gene silencing cancer therapeutics - ValiRx

Drug Profile

Research programme: gene silencing cancer therapeutics - ValiRx

Alternative Names: VAL-101

Latest Information Update: 01 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ValiRx plc
  • Developer ValiRx
  • Class DNA-binding proteins
  • Mechanism of Action Genetic transcription inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 01 Feb 2016 Preclinical development is ongoing in United Kingdom
  • 26 Jun 2008 Preclinical trials in pancreatic cancer in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top